The estimated Net Worth of Eric K Rowinsky is at least $6.11 Milhão dollars as of 15 February 2024. Eric Rowinsky owns over 455 units of Biogen Inc stock worth over $4,107,028 and over the last 15 years he sold BIIB stock worth over $1,594,724. In addition, he makes $411,143 as Independent Director at Biogen Inc.
Eric has made over 16 trades of the Biogen Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 455 units of BIIB stock worth $101,256 on 15 February 2024.
The largest trade he's ever made was selling 30,000 units of Biogen Inc stock on 1 January 2021 worth over $127,200. On average, Eric trades about 1,924 units every 64 days since 2010. As of 15 February 2024 he still owns at least 20,629 units of Biogen Inc stock.
You can see the complete history of Eric Rowinsky stock trades at the bottom of the page.
Dr. Eric K. Rowinsky, M.D. is an Independent Director of Biogen Inc. Dr. Rowinsky has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2016. Since June 2016 Dr. Rowinsky has also been the Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones. From January 2012 to November 2015 Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009 he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996 Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky also serves as a director of Biophytis, a biotechnology company, and Fortress Biotech Inc. and Verastem, Inc., both biopharmaceutical companies.
As the Independent Director of Biogen Inc, the total compensation of Eric Rowinsky at Biogen Inc is $411,143. There are 16 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Eric's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, eStelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: